TGI 14
Alternative Names: TGI-14Latest Information Update: 24 Nov 2023
Price :
$50 *
At a glance
- Originator TG ImmunoPharma
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Research Cancer
Most Recent Events
- 04 Oct 2023 TGI 14 is available for licensing as of 04 Oct 2023. https://www.tgimmunopharma.com/partnerships
- 04 Oct 2023 Early research in Cancer in China (Parenteral), prior to October 2023 (TG ImmunoPharma pipeline, October 2023)